PHOENIX, Ariz. Sept. 23, 2011 The Translational Genomics Research Institute (TGen) is part of a team of medical investigators receiving a $3.5 million grant from Susan G. Komen for the Cure to study triple-negative breast cancer, a highly aggressive form of this cancer that disproportionately affects African-Americans.
The Komen Foundation recently called for proposals from teams of physicians and scientists called Promise Grants, multi-million dollar, multi-year, collaborative grants aimed at answering the most difficult questions in breast cancer and translating their findings into outcomes that will impact patient care.
Only three teams were selected for funding for this highly competitive program. The team leaders for this proposal are: Dr. Jeffrey Trent of Phoenix-based TGen; Dr. Pat LoRusso of the Karmonos Cancer Institute in Detroit; and Dr. Max Wicha of The University of Michigan Comprehensive Cancer Center. Other centers collaborating on this project include the Van Andel Research Institute (VARI) in Grand Rapids, which is TGen's affiliate, and the Baylor College of Medicine in Houston.
The collective expertise of these oncologists and basic scientists will be brought to bear on this landmark translational research study. Three specific biomarkers that are used to determine breast cancer treatment are missing in triple-negative breast cancer. The most successful treatment advances in breast cancer have targeted these three markers. None of these therapies are effective in triple-negative breast cancer.
"We hope to uncover new ways of treating this very aggressive form of breast cancer by understanding the molecular makeup of breast cancer stem cells," said Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division, who is leading other translational investigations into triple-negative breast cancer and is a co-investigator on the new Komen study. "Our goal is to unlock the clues as to why pa
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute